China Biotech Services Holdings Limited (HKG:8037)
0.6100
-0.0050 (-0.81%)
Sep 11, 2026, 2:53 PM HKT
HKG:8037 Revenue
China Biotech Services Holdings had revenue of 37.23M HKD in the half year ending June 30, 2026, with 14.72% growth. This brings the company's revenue in the last twelve months to 85.86M, up 11.61% year-over-year. In the year 2025, China Biotech Services Holdings had annual revenue of 73.50M with 4.25% growth.
Revenue (ttm)
85.86M
Revenue Growth
+11.61%
P/S Ratio
6.99
Revenue / Employee
517.25K
Employees
166
Market Cap
600.07M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.50M | 2.99M | 4.25% |
| Dec 31, 2024 | 70.51M | -141.48M | -66.74% |
| Dec 31, 2023 | 211.99M | -1.64B | -88.55% |
| Dec 31, 2022 | 1.85B | 1.23B | 196.83% |
| Dec 31, 2021 | 623.76M | -32.03M | -4.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 8.02B |
| Adicon Holdings | 3.06B |
| Kindstar Globalgene Technology | 1.10B |
| Yunkang Group | 624.49M |
| Mega Genomics | 413.73M |
| Biosino Bio-Technology and Science Incorporation | 196.98M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |